About us Pricing ContactSubscribe

R

Richard G. Langley

Dalhousie UniversityORCID https://orcid.org/0000-0003-4730-2164

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Psoriasis: epidemiology, clinical features, and quality of life

Annals of the Rheumatic Diseases20051,094 citationsFirst authorCorresponding

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology2007872 citations

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

British Journal of Dermatology2007720 citations

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology2015659 citations

Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

Journal of the American Academy of Dermatology2004603 citationsFirst authorCorresponding

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

British Journal of Dermatology2016450 citations

Richard G. Langley · Scinovex